Cover Image
市場調查報告書

全球纖維蛋白原市場及產品平台分析

Analysis of the Global Fibrinogen Market and Product Pipeline

出版商 Frost & Sullivan 商品編碼 346559
出版日期 內容資訊 英文 54 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球纖維蛋白原市場及產品平台分析 Analysis of the Global Fibrinogen Market and Product Pipeline
出版日期: 2015年12月08日 內容資訊: 英文 54 Pages
簡介

由於纖維蛋白原的需求擴大,以及噴劑,貼片等創新給藥系統的開發,全球纖維蛋白原市場正在加速擴大中。

本報告提供全球纖維蛋白原市場相關調查,提供您市場現狀與到2020年前的成長預測,並彙整競爭環境,開發平台及臨床實驗趨勢等資料。

第1章 摘要整理

第2章 調查方法與調查範圍

第3章 市場背景

  • 市場概要:簡介
  • 血漿生產
  • 市場區隔
  • 血漿市場佔有率
  • 纖維蛋白原生產
  • 收益預測
  • 考察
  • 供應鏈和流通網

第4章 競爭環境:人類用纖維蛋白原(已上市及開發中產品)

第5章 極為重要的第三期臨床試驗

  • 纖維蛋白原市場:持續中/最近完成的臨床實驗
  • 關注的主要產品摘要
  • 主要的活動計劃:產品上市

第6章 產品開發動態即時看板系統(已上市及第三階段產品)

  • Haemocomplettan/RiaSTAP
  • Clottafact
  • Octafibrin
  • Artiss
  • Evarrest
  • Raplixa
  • FS Grifols

第7章 結論

  • 結論
  • 法律上的免責聲明

第8章 Frost & SUllican案例

目錄
Product Code: MB93-01-00-00-00

Launch of Topical and Ready-to-Use Fibrin Sealants Impetus to Growth

The increased demand for fibrinogen and the development of innovative delivery systems such as sprays and patches are fuelling the growth of the fibrinogen market. This research service provides a detailed assessment of the global fibrinogen market, covering the current market scenario and growth prospects for the period 2015-2020. Both marketed and pipeline products are segmented based on their therapeutic uses, namely, deficiency therapy and operative care. An elaborate discussion on clinical trial timelines and results, along with historical and projected launch timelines, has been provided. The study also discusses key companies such as CSL Behring, LFB, Baxter Healthcare, Takeda, Grifols, and Octapharma.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary-Key Findings
  • 2. Executive Summary-Key Findings (continued)
  • 3. Key Trends
  • 4. Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. MARKET BACKGROUND

Market Background

  • 1. Market Overview-Introduction
  • 2. Market Overview-Blood Plasma Production
  • 3. Market Segmentation
  • 4. Blood Plasma Market Share
  • 5. Fibrinogen Production
  • 6. Revenue Forecast
  • 7. Revenue Forecast Discussion
  • 8. Supply Chain and Distribution Network
  • 9. Supply Chain and Distribution Network (continued)

4. COMPETITIVE LANDSCAPE-HUMAN FIBRINOGEN (MARKETED AND PIPELINE PRODUCTS)

Competitive Landscape-Human Fibrinogen (Marketed and Pipeline Products)

  • 1. Competitive Landscape-Marketed and Pipeline Products
  • 2. Competitive Landscape Overview
  • 3. Marketed Products-Deficiency and Other Therapies
  • 4. Pipeline Products-Deficiency and Other Therapies
  • 5. Marketed Products-Operative Care
  • 6. Marketed Products-Operative Care (continued)
  • 7. Pipeline Products-Operative Care

5. PIVOTAL PHASE 3 TRIALS

Pivotal Phase 3 Trials

  • 1. Fibrinogen Market-Major On-going/Recently Completed Clinical Trials
  • 2. Fibrinogen Market-Major On-going/Recently Completed Clinical Trials (continued)
  • 3. Fibrinogen Market-Major On-going/Recently Completed Clinical Trials (continued)
  • 4. Summary of Key Products to Watch
  • 5. Summary of Key Products to Watch (continued)
  • 6. Timeline of Key Events-Launch of Products

6. PRODUCT DASHBOARD (KEY MARKETED AND PHASE 3 PRODUCTS)

Product Dashboard (Key Marketed and Phase 3 Products)

  • 1. Product Dashboard-Haemocomplettan/RiaSTAP (CSL Behring)
  • 2. Product Dashboard-Clottafact (LFB)
  • 3. Product Dashboard-Octafibrin (Octapharma)
  • 4. Product Dashboard-Artiss (Baxter Healthcare)
  • 5. Product Dashboard-Evarrest (Ethicon)
  • 6. Product Dashboard-Raplixa (The Medicines Company)
  • 7. Product Dashboard-FS Grifols (Grifols)

7. CONCLUSIONS

Conclusions

  • 1. Conclusions
  • 2. Legal Disclaimer

8. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition-Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
Back to Top